GlassScriptPhysician profile
Matthew C Whittington
NPI 1780794594
$3,655.23
in general payments reported to CMS, 2019-2025
25 companies · $745 in 2025
The $745 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $151 · 2021: $644 · 2022: $431 · 2023: $526 · 2024: $774 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Debt Forgiveness: $34.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.99 |
| Debt Forgiveness | $34.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $432.21 | 2022-2025 | Azstarys |
| Pfizer INC. | $366.71 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $346.04 | 2021-2025 | Qelbree |
| Tris Pharma INC | $317.26 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Ironshore Pharmaceuticals INC. | $305.39 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $270.64 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Collegium Pharmaceutical, INC. | $235.36 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $228.43 | 2020-2022 | |
| Glaxosmithkline, LLC. | $223.01 | 2019-2025 | Pediarix, Bexsero, Menveo |
| Sobi, INC | $207.04 | 2019-2022 | |
| Sanofi Pasteur INC. | $130.09 | 2019-2025 | |
| Baxter Healthcare | $108.95 | 2022-2023 | |
| Qol Medical, LLC | $95.95 | 2022-2025 | Sucraid, Sucraid |
| Shire North American Group INC | $75.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $59.38 | 2024-2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $57.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $51.05 | 2023-2024 | Flumist Quadrivalent |
| Neos Therapeutics, LP | $29.47 | 2019 | |
| Mission Pharmacal Company | $20.02 | 2019 | |
| Genzyme Corporation | $19.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.49 | 2024 | |
| Novo Nordisk INC | $17.24 | 2025 | Wegovy |
| Ibsa Pharma INC. | $15.63 | 2022 | |
| Aytu Biopharma, INC. | $14.09 | 2025 | |
| Pbg Puerto Rico LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Whittington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.